Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments
Abstract Psoriasis is a chronic inflammatory disease with a well-documented negative effect on the quality of life of affected patients. Psoriasis often occurs in the reproductive years, during which the issue of pregnancy needs to be addressed. The course of psoriasis during pregnancy is unpredictable, and many patients face the challenge of needing treatment during pregnancy. In this review we provide an overview of the key considerations for managing psoriasis in pregnant women, covering the potential effects of active psoriasis and co-morbid conditions on the health of the mother and fetus, as well as the effects of psoriasis treatment options on the developing fetus. Although there are no robust data on the safety of systemic treatment of pregnant women, increasing evidence regarding the safety of cyclosporine (ciclosporin) treatment as well as anti-tumor necrosis factor-α is available and should be considered in pregnant women with moderate to severe psoriasis unresponsive to local corticosteroids and UVB light treatment..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
American journal of clinical dermatology - 16(2015), 5 vom: 07. Juli, Seite 389-398 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bangsgaard, Nannie [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Adverse Pregnancy Outcome |
---|
doi: |
10.1007/s40257-015-0137-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR032964234 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR032964234 | ||
003 | DE-627 | ||
005 | 20230519150808.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40257-015-0137-5 |2 doi | |
035 | |a (DE-627)SPR032964234 | ||
035 | |a (SPR)s40257-015-0137-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Bangsgaard, Nannie |e verfasserin |4 aut | |
245 | 1 | 0 | |a Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Psoriasis is a chronic inflammatory disease with a well-documented negative effect on the quality of life of affected patients. Psoriasis often occurs in the reproductive years, during which the issue of pregnancy needs to be addressed. The course of psoriasis during pregnancy is unpredictable, and many patients face the challenge of needing treatment during pregnancy. In this review we provide an overview of the key considerations for managing psoriasis in pregnant women, covering the potential effects of active psoriasis and co-morbid conditions on the health of the mother and fetus, as well as the effects of psoriasis treatment options on the developing fetus. Although there are no robust data on the safety of systemic treatment of pregnant women, increasing evidence regarding the safety of cyclosporine (ciclosporin) treatment as well as anti-tumor necrosis factor-α is available and should be considered in pregnant women with moderate to severe psoriasis unresponsive to local corticosteroids and UVB light treatment. | ||
650 | 4 | |a Psoriasis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Preterm Birth |7 (dpeaa)DE-He213 | |
650 | 4 | |a Topical Corticosteroid |7 (dpeaa)DE-He213 | |
650 | 4 | |a Adverse Pregnancy Outcome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Ustekinumab |7 (dpeaa)DE-He213 | |
700 | 1 | |a Rørbye, Christina |e verfasserin |4 aut | |
700 | 1 | |a Skov, Lone |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of clinical dermatology |d Berlin [u.a.] : Springer, 2000 |g 16(2015), 5 vom: 07. Juli, Seite 389-398 |w (DE-627)SPR032954131 |w (DE-600)2043675-0 |x 1179-1888 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2015 |g number:5 |g day:07 |g month:07 |g pages:389-398 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40257-015-0137-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 16 |j 2015 |e 5 |b 07 |c 07 |h 389-398 |